Ergun, T. Et Al. 2023. Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.. Vaccine , vol.41, no.29 , 4287-4294.

Ergun, T., Hosgoren Tekin, S., Apti Sengun, O., Akin Cakici, O., Seckin, D., Adiay, C., ... Enul, H.(2023). Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.. Vaccine , vol.41, no.29, 4287-4294.

Ergun, Tulin Et Al. "Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.," Vaccine , vol.41, no.29, 4287-4294, 2023

Ergun, Tulin Et Al. "Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.." Vaccine , vol.41, no.29, pp.4287-4294, 2023

Ergun, T. Et Al. (2023) . "Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.." Vaccine , vol.41, no.29, pp.4287-4294.

@article{article, author={Tulin Ergun Et Al. }, title={Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.}, journal={Vaccine}, year=2023, pages={4287-4294} }